Editors Note: This article was republished with permission from Martin Lee and the www.projectcbd.org website.
Many scientists don’t have big public relations teams to promote their work or work at companies that employ marketing efforts to make their achievements known. Instead, they toil away in labs, most unrecognized for their hard work. Green Market Report is happy to give these women the accolades they deserve.
Allyn Howlett, PhD, is a pioneer neuropharmacologist known for her groundbreaking discovery of the CB1 cannabinoid receptor in 1988. Initially identified by Howlett and her graduate student, William Devane, at the St. Louis School of Medicine, CB1 receptors are the most abundant G-protein coupled receptors in the mammalian brain. This discovery opened the floodgates of research into the endocannabinoid system with huge implications for nearly every area of medical science. Howlett is currently a professor in the Department of Physiology and Pharmacology at the Wake Forest School of Medicine in Winston-Salem, North Carolina, where the Howlett Lab is studying protein interactions that modulate cannabinoid receptor activity in an effort to advance the development of new cannabinoid medicines. Read more here.
Cecilia Hillard, PhD, is the Associate Dean for Research and Director of the Neuroscience Research Center at the Medical College of Wisconsin in Milwaukee, where her lab focuses on the pharmacology and biochemistry of cannabinoids and endocannabinoids. Her work has contributed significantly to understanding how cannabinoids regulate immune function and the role of endocannabinoid signaling in the regulation of mood and responses to stress. An outstanding mentor to medical students and scientists, Hillard is the recipient of many honors, including the Lifetime Achievement Award from the International Cannabinoid Research Society (ICRS). She currently serves as executive director of the ICRS.
Heather Bradshaw, PhD, is an Associate Professor in the Department of Psychological & Brain Sciences at Indiana University in Bloomington, where she directs the Bradshaw Lab of Lipid Neuroscience. Her studies focus on how endocannabinoids and related lipid molecules impact female reproductive neurophysiology. Bradshaw’s team is examining disease models of endometriosis, chronic pain, and neuroinflammation and their link to aberrant lipid signaling in the endocannabinoid system. A past president of the International Cannabinoid Research Society, Bradshaw has published over sixty journal articles and frequently lectures at universities and conferences around the world.
Andrea Hohmann, PhD, is chairwoman of the Gill Center for Biomolecular Science at Indiana University in Bloomington. One of the world’s foremost experts on neuropathic pain and the endocannabinoid system, Hohmann is seeking to develop novel therapeutic interventions for promoting analgesia that lack abuse liability and adverse side effects. Hohmann’s lab has demonstrated that nonopioid stress-induced analgesia is mediated by the release of endocannabinoids. In addition to mapping cannabinoid receptors within pain pathways, she has been researching the potential benefits of administering cannabinoids and opioids in combination. Hohmann and her colleagues have shown that activating the CB2 cannabinoid receptor can prevent opioid tolerance and reduce symptoms of opioid withdrawal.